Treatment of postrenal transplant erythrocytosis. Long-term efficacy and safety of angiotensin-converting enzyme inhibitors

Nephron. 1996;74(3):517-21. doi: 10.1159/000189445.

Abstract

Fifty-two patients with postrenal transplant erythrocytosis were treated with an angiotensin-converting enzyme inhibitor (lisinopril or enalapril) for a median of 13 months (range 0-44). A significant fall in haemoglobin of 1.8 +/- 1.6 g dl-1 (range - 0.8 to 6.6) occurred over the first 3 months (p < 0.0001). The haemoglobin then remained stable for as long as 3 years. Both enalapril and lisinopril were equally effective. Therapy was withdrawn in 16 patients (31%) because of decline in renal function (6), anaemia (5), hypotension (3), hyperkalaemia (1) or erectile impotence (1) - complications which were all reversible. Angiotensin-converting enzyme inhibitors in low dose are a safe and effective long-term therapy for postrenal transplant erythrocytosis.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Drug Administration Schedule
  • Enalapril / adverse effects
  • Enalapril / therapeutic use*
  • Female
  • Hemoglobins / drug effects
  • Hemoglobins / metabolism
  • Humans
  • Kidney Transplantation / adverse effects*
  • Lisinopril / adverse effects
  • Lisinopril / therapeutic use*
  • Male
  • Middle Aged
  • Polycythemia / drug therapy*
  • Polycythemia / etiology

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Hemoglobins
  • Enalapril
  • Lisinopril